Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine

References

• Allen A. Vaccine. The Controversial Story of Medicine’s Greatest Lifesaver (1st Edition). WW Norton & Company, NY, USA (2007).
   Google Scholar
• Baker JP, Katz SL. Childhood vaccine development: an overview. Pediatr. Res.55, 347–356 (2004).
   PubMed Web of Science ®Google Scholar
• Offit PA. The Cutter incident, 50 years later. N. Engl. J. Med.352, 1411–1412 (2005).
   PubMed Web of Science ®Google Scholar
• Wakefield AJ, Murch SH, Anthony A et al. Ileal-lymphodi-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet351, 637–641 (1998).
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. An assessment of downward trends in neurodevelopmental disorders in the United States following removal of thimerosal from childhood vaccines. Med. Sci. Monit.12, CR231–CR239 (2006).
   PubMed Web of Science ®Google Scholar
• Immunization Safety Review Committee. Immunization Safety Review: Vaccines and Autism. National Academy Press, WA, USA (2004).
   Google Scholar
• Stewart GT. Vaccination against whooping-cough. Efficacy versus risks. Lancet1(8005), 234–237 (1977).
   PubMed Web of Science ®Google Scholar
• Miller DL, Alderslade R, Ross EM. Whooping cough and whooping cough vaccine: the risks and benefits debate. Epidemiol. Rev.4, 1–24 (1982).
   PubMed Web of Science ®Google Scholar
• Miller DL, Ross EM, Alderslade R, Bellman MH, Rawson NSB. Pertussis immunization and serious acute neurological illness in children. Br. Med. J. (Clin. Res. Ed.)292, 1595–1599 (1982).
   Google Scholar
• Gale LG, Purushottam BT, Wassilak SGF et al. Risk of serious acute neurological illness after immunisation with diphtheria–tetanus–pertussis vaccine. JAMA271, 37–41 (1994).
   PubMed Web of Science ®Google Scholar
• Griffith AH. Permanent brain damage and pertussis vaccination: is the end of the saga in sight? Vaccine7, 199–210 (1989).
   PubMed Web of Science ®Google Scholar
• Piyasirisilp S, Hemachudha T. Neurological adverse events associated with vaccination. Curr. Opin. Neurol.15, 333–338 (2002).
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Prevention of poliomyelitis: recommendations for use of only inactivated poliovirus vaccine for routine immunization. Pediatrics104, 1404–1406 (1999).
   PubMed Web of Science ®Google Scholar
• Kinnunen E, Junttila O, Haukka J, Hovi T. Nationwide oral polio vaccinatjon campaign and the incidence of Guillain–Barré syndrome. Am. J. Epidemiol.147, 69–73 (1998).
   PubMed Web of Science ®Google Scholar
• Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al. Guillain–Barré syndrome following vaccination in the National Influenza Immunization Programme, United States, 1976–1977. Am. J. Epidemiol.110, 105–123 (1979).
   PubMed Web of Science ®Google Scholar
• Safranek TJ, Lawrence DN, Kurland LT et al. Reassessment of the association between Guillain–Barré syndrome and receipt of swine influenza vaccine in 1976–1977. Am. J. Epidemiol.133, 940–951 (1991).
   PubMed Web of Science ®Google Scholar
• Lasky T, Terracciano GJ, Magder L et al. The Guillain–Barré syndrome and the 1992–93 and 1993–94 influenza vaccines. N. Engl. J. Med.339, 1797–1802 (1998).
   PubMed Web of Science ®Google Scholar
• Haber P, DeStefano F, Angulo FJ et al. Guillain–Barré syndrome following influenza vaccination. JAMA292, 2478–2481 (2004).
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. Risks of convulsions an aseptic meningitis following measles–mumps–rubella vaccination in the United Kingdom. Am. J. Epidemiol.165, 704–709 (2007).
   PubMed Web of Science ®Google Scholar
• Grose C, Spigland I. Guillain–Barré syndrome following administration of live measles vaccine. Am. J. Med.60, 441–443 (1976).
   PubMed Web of Science ®Google Scholar
• Patja A, Paunio M, Kinnunen E, Junttila O, Hovi T, Peltola H. Risk of Guillain–Barré syndrome after measles–mumps–rubella vaccination. J. Pediatr.138, 250–254 (2000).
   Web of Science ®Google Scholar
• Fourrier A, Touzé E, Alpérovitsch A, Bégaud B. Association between hepatitis B vaccines and multiple sclerosis. Pharmacoepidemiol. Drug Saf.8, S140–S141 (1999).
   Google Scholar
• Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine23, 3876–3886 (2005).
   PubMed Web of Science ®Google Scholar
• Ascherio A, Zhang SM, Hernan MA et al. Hepatitis B vaccination and the risk of multiple sclerosis. N. Engl. J. Med.344, 327–332 (2001).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Suissa S, Saddieer P, Bourdes V, Vukusoc S. Vaccines in multiple sclerosis study group. Vaccination and the risk of relapse in multiple sclerosis. N. Engl. J. Med.344, 319–326 (2001).
   PubMed Web of Science ®Google Scholar
• HogenEseh H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine20, S34–S39 (2002).
   PubMed Web of Science ®Google Scholar
• Clemens CJ, Griffiths E. The global impact of vaccines containing aluminum adjuvants. Vaccine20, S24–S33 (2002).
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunisation with aluminum-containing DTP-vaccines: systematic review of the evidence. Lancet Infect. Dis.4, 84–90 (2004).
   PubMed Web of Science ®Google Scholar
• Bergfors E, Björkelund C, Trollfors B. Nineteen cases of persistent pruriticnodulesn and contact allergy to aluminum after injection of commonly used aluminum-adsorbed vaccines. Eur. J. Pediatr.164, 691–697 (2005).
   PubMed Web of Science ®Google Scholar
• Netterlid E, Bruze M, Hindsén M, Isaksson M, Olin P. Persistent itching nodules after the fourth dose of diphtheria–tetanus toxoid vaccines without evidence of delayed hypersensitivity to aluminum. Vaccine22, 3698–3706 (2004).
   PubMed Web of Science ®Google Scholar
• Pittman PR. Aluminum-containing vaccine associated with adverse events: role of route of administration and gender. Vaccine20, S48–S50 (2002).
   PubMed Web of Science ®Google Scholar
• Gherardi RK, Coquet M, Chérin P et al. Macrophagic myofasciitis: an emerging entity. Lancet352, 347–352 (1998).
   PubMed Web of Science ®Google Scholar
• Nevo Y, Kutai M, Jossiphov J et al. Childhood macrophagic myofasciitis – consanguinity and clinicopathological features. Neuromuscul. Disord.14, 246–252 (2004).
   PubMed Web of Science ®Google Scholar
• Gherardi RK, Coquet M, Belec L et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminum hydroxide in muscle. Brain124, 1821–1831 (2001).
   PubMed Web of Science ®Google Scholar
• Siegrist CA. Vaccine adjuvants and macrophagic myofasciitis. Bull. Acad. Natl Med.187, 1511–1521 (2003).
   PubMed Web of Science ®Google Scholar
• WHO Vaccine Safety Advisory Committee. Aluminum containing vaccines and macrophagic myofasciitis. Wkly Epidemiol. Rec.77, 389–394 (2002).
   PubMedGoogle Scholar
• Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine ‘Folkehelsa’: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14, 67–80 (1991).
   PubMedGoogle Scholar
• Bjune G, Høiby EA, Grønnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338, 1093–1096 (1991).
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet2(8346), 355–357 (1983).
   PubMed Web of Science ®Google Scholar
• Sierra GVG, Campa HC, Varacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial a mass vaccination results in Cuba. NIPH Ann.14, 195–207 (1991).
   PubMedGoogle Scholar
• Tuttle J, Chen RT, Rantala H, Cherry JD, Rhodes PH, Hadler S. The risk of Guillain–Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am. J. Public Health87, 2045–2048 (1997).
   PubMed Web of Science ®Google Scholar
• Nøkleby H, Aavitsland P, O’Hallahan J, Feiring B, Tilman S, Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitides serogroup B disease. Vaccine25, 3080–3084 (2007).
   PubMed Web of Science ®Google Scholar
• Cusi MG. Applications of influenza virosomes as a delivery system. Hum. Vaccin.2, 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine19, 2673–2680 (2001).
   PubMed Web of Science ®Google Scholar
• Tong NK, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int.68, 2298–2303 (2005).
   PubMed Web of Science ®Google Scholar
• van der Laan JW. Adjuvants enhancing an integral immune response to antigens. Expert Rev. Vaccines4, 15–18 (2005).
   PubMedGoogle Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354, 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a Phase I randomised controlled trial. Lancet368, 991–997 (2006).
   PubMed Web of Science ®Google Scholar
• Ball R. Methods of ensuring vaccine safety. Expert Rev. Vaccines1, 161–168 (2002).
   PubMedGoogle Scholar
• Iskander JK, Miller ER, Chen RT. The role of the Vaccine Adverse Event Reporting System (VAERS) in monitoring vaccine safety. Pediatr. Ann.33, 599–606 (2004).
   PubMed Web of Science ®Google Scholar
• Kohl KS, Bonhoeffer J, Chen R et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol. Drug Saf.12, 335–340 (2003).
   PubMed Web of Science ®Google Scholar
• Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA285, 1183–1185 (2001).
   PubMed Web of Science ®Google Scholar
• Alaszewski A, Horlick-Jones T. How can doctors communicate information about risk more effectively? Br. Med. J. (Clin. Res. Ed.)377, 728–731 (2003).
   Google Scholar